Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US
Tunis SL, Minshall ME, St.Charles M, Pandya BJ, Baran RW

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1185/03007990802434874

Indexing Status
Subject indexing assigned by CRD

MeSH
Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Metformin; Quality-Adjusted Life Years; Thiazolidinediones; United States

AccessionNumber
22009102546

Date bibliographic record published
24/02/2010